Expedition Medicines

Expedition Medicines is an early-stage biotech leveraging a proprietary platform at the intersection of covalent chemistry and AI to tackle undruggable targets. Its platform integrates high-throughput chemoproteomic data generation with advanced generative AI and quantum chemistry calculations to design molecules that form covalent bonds with protein surfaces. Backed by Flagship Pioneering and led by a team of experts in covalent drug discovery and AI, the company is building a pipeline of novel therapeutics while seeking to fundamentally expand the druggable proteome.

Integrated platform combining covalent chemistry, high-throughput chemoproteomic data generation, and generative AI/quantum chemistry algorithms to design small molecules that engage 'undruggable' protein surfaces.

Expedition competes in the crowded AI-drug discovery sector (e.g., Recursion, Exscientia, Insilico Medicine) and the specialized covalent drug discovery niche (e.g., Relay Therapeutics, Frontier Medicines). Its differentiation lies in the specific integration of proteome-wide covalent chemistry data with generative AI, a approach few, if any, competitors have fully replicated.